NEW YORK, June 25, 2014 (GLOBE NEWSWIRE) -- Lyfebulb, an organization dedicated to helping people achieve their optimal lifestyle by addressing general and chronic health concerns, and Immune Pharmaceuticals Inc. (OTCQX:IMNP) (Nasdaq:IMNP) co-hosted the third Lyfebulb event on June 19th at Brasserie Ruhlmann in New York. The event provided an opportunity for guests to connect and learn about emerging and personalized therapies in Crohn's and Colitis Disease, also known as Inflammatory Bowel Disease (IBD). The event's host committee included Lyfebulb founder and renowned health and wellness expert, Dr. Karin Hehenberger, Dr. Daniel Teper, the CEO of Immune Pharmaceuticals, and Dr. James Aisenberg, distinguished gastroenterologist and Associate Clinical Professor of Medicine at The Mount Sinai Hospital.
Help employers find you! Check out all the jobs and post your resume.
